Award-winning Hong Kong cha chaan teng Keming Bing Sat to make Singapore debut in late May, Lifestyle News
Set to open at Plaza Singapura in late May, this will be the chain's first outlet in Singapore.
Since their launch in Hong Kong in 2019, Keming Bing Sat has garnered massive popularity and currently has 140 outlets across Hong Kong and Mainland China.
They've also won several accolades — with their roast meats being recognised by the China Dining Industry Association as a Traditional Chinese Intangible Cultural Heritage Dish.
Frost & Sullivan, a market research company, also named the chain's char siew rice as the 'No.1 Best-Selling Char Siew Rice' in China based on sales from April 2024 to March 2025.
According to a press release, it boasted a sales volume of over 3.3 million portions sold in China over a single year.
Some dishes that diners can expect at the new Singapore outlet include the award-winning signature Char Siew Rice — touted to be crafted by "a Hong Kong roast meat master with 40 years of experience".
The dish includes caramelised char siew, two soft-fried eggs and Wuchang rice (said to be a premium variety of japonica rice), complete with a secret sauce made in-house with 23 ingredients.
To go with your meal, there are also beverages like the Little Bear Iced Lemon Tea and Little Bear Iced Hong Kong Milk Tea — featuring a frozen 'little bear' sitting atop the drinks — both of which went viral online in 2019, according to the press release.
For dessert, diners can indulge in sweet treats such as the Lava Oreo Toast or Happiness Lava Egg Waffles — inspired by the traditional Hong Kong eggette.
According to the brand, the restaurant's offerings are reflective of their concept of "Yesterday's Hong Kong, Today's Shenzhen" — honouring traditions while remaining innovative.
[[nid:700296]]
carol.ong@asiaone.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
3 hours ago
- Straits Times
Hong Kong-listed Chinese pharma sets sights on SGX for secondary listing
Sign up now: Get ST's newsletters delivered to your inbox The proposed listing will not involve issuing new shares, and China Medical System will continue to be primarily traded in Hong Kong. SINGAPORE – A Hong Kong-listed pharmaceutical company is aiming to launch a secondary listing on the Singapore Exchange (SGX) later this month. China Medical System (CMS) filed its preliminary prospectus with the Monetary Authority of Singapore on June 27. The proposed listing will not involve issuing new shares, and CMS will continue to be primarily traded in Hong Kong, where it listed in 2010. CMS said Singapore is the 'ideal launch place' for its high-value innovations given the country's highly developed economy, robust IP protections, skilled talent pool and trade agreements. It will use Singapore as a base to expand across South-east Asia and the Middle East, while employing the listing here to attract funds. 'The SGX listing marks a strategic step to deepen our regional footprint, boost visibility among South-east Asian stakeholders, and reinforce our reputation as a high-quality, innovation-led pharmaceutical player,' the company said. It added that its regional expansion is being driven by the need to bolster supply chains. CMS, which was set up in 1992, produces around 40 products that focus on three areas of healthcare: Cardio-cerebrovascular and gastroenterology; dermatology and medical aesthetics; and ophthalmology. Its financial performance in 2023 and 2024 was impacted by a new policy in China that centralised bidding and consolidated procurement processes in order to lower drug and medical device costs for public hospitals. Three of CMS's drugs fell under the new regulations but revenue rebounded in the second half of last year, allowing the firm to post profits of 1.61 billion yuan (S$290 million) in 2024. The company highlighted four key platforms to boost its presence across Asia-Pacific, including its research and development arm and PharmaGend, the firm's development and manufacturing platform for regional manufacturing and supply. In December 2023, PharmaGend acquired a manufacturing facility in Tuas, which is expected to ship its first productions for the US market in the second half of this year. CMS said it plans to add to its 200-strong workforce here, and will also outlay US$200 million to double capacity at the Tuas plant, a project that is expected to be fully operational by the end of 2028. The firm stated that the Singapore facility, which can produce one billion tablets a year, eases supply chain risks by localising production for regional and Middle East markets. 'This aligns with Asean's push for self-sufficiency in essential medicines and positions CMS as a reliable partner in regional health security,' it added. South-east Asia's pharmaceutical market is projected to hit a volume of US$18.28 billion by 2030, with an annual growth of 4.9 per cent. The CMS listing will be the second on the mainboard this year, after the initial public offering of local firm Info-Tech Systems, which begins trading on July 4. Last week, Japan's telco giant Nippon Telegraph and Telephone filed its preliminary prospectus for a data centre Reit, which could mark SGX's largest Reit listing since 2013.
CNA
5 hours ago
- CNA
Alibaba looking to raise $1.53 billion through exchangeable bonds for cloud, commerce push
Chinese tech giant Alibaba Group said on Thursday it is seeking to raise around HK$12 billion ($1.53 billion) through exchangeable bonds to boost investments in cloud infrastructure and global commerce operations. The bonds link to Alibaba Health Technology , the group said. Investors can later exchange these bonds for shares in Alibaba Health, and the bonds will not pay interest over time. Alibaba Group holds more than 44 per cent of Alibaba Health. The debt sale follows Alibaba's $5 billion dual-currency bond in November, which was the largest deal of its kind in Asia-Pacific during 2024. Thursday's offering comes as more investors tap the Asian credit market after monetary and fiscal stimulus by Beijing policymakers improved the region's debt appeal.. Hong Kong-listed shares of Alibaba Group closed 2.9 per cent lower at HK$106.20 on Thursday, while Alibaba Health stock ended down 2.8 per cent.
CNA
9 hours ago
- CNA
Hong Kong retailers under strain as changing trends drive store closures
HONG KONG: Hong Kong's retailers are battling against shifting consumer habits, as visitors spend less and locals head across the border to China for cheaper dining and shopping, leading to a wave of store closures. A 36-year-old Chinese seafood restaurant chain and a popular high-end food court in the bustling Causeway Bay district closed this week. Other recent closures in the financial hub include cinema chains, a major catering group, a 41-year-old bakery and a three-decade-old congee chain. Weak domestic spending and cheaper prices in Shenzhen, bordering Hong Kong, have compounded retailers' woes, according to industry figures and analysts. Furthermore, China's economic slowdown, US-China geopolitical tensions and a national security clampdown have also weighed on business sentiment and hurt Hong Kong's small and open economy. The city's GDP is forecast to grow between 2 per cent - 3 per cent this year, compared with 2.5 per cent last year and 3.2 per cent in 2023. "The change in consumption patterns is irreversible," said Annie Yau Tse, chairwoman of Hong Kong's Retail Management Association. Hong Kong was once a prime destination for high-spending mainland visitors but mass anti-government protests in 2019 and COVID restrictions led to a decline in its appeal. The authorities have launched initiatives to revive tourism, including hosting large-scale events such as Coldplay concerts and a Manchester United exhibition match at a new harbourside stadium. While visitors are returning to near 2018 levels with May arrivals up 20 per cent to 4.08 million visitors versus 4.95 million in 2018, spending remains soft. Retail sales by value rose 2.4 per cent in May from a year earlier to HK$31.3 billion (US$4 billion), the first rise in 14 months, government data showed on Wednesday. However, it remains only around 77 per cent of the HK$40.5 billion in May 2018. "We are trying hard to think of ways to turn the traffic into business," Yau Tse said. Jack Tong, director of Savills Research & Consultancy, said the recent string of closures was due to a "structural shift in the local retail market" starting from 2023. It is "no longer strong enough to support such retail trades and would be beyond repair even by further reducing rents." Overall prime street rents in the first quarter have fallen back to 2003 levels, he said. "The rise in local outbound travel in Hong Kong and changes in mainland tourists' spending patterns and preferences in Hong Kong and Macau continued to weigh on the overall retail sector during the financial year," jeweller Chow Tai Fook said. Last month, Cafe de Coral reported a 29.6 per cent drop in net profit for the 2024/25 year ended in March, citing a weak economy and consumer sentiment. Despite the tough conditions, some signs of recovery are emerging. Vipul Sutariya, who attended the jewellery fair in June, said Chinese dealers were back at the fair "not to buy immediately but to ask, which is the biggest change in the past 1.5 years," he said. "In my view that's a good sign."
